Founded in Somerville, United States, Finch Therapeutics Group, Inc. is a biopharmaceutical company dedicated to developing and delivering innovative microbial therapies aimed at addressing serious unmet medical needs. As an early pioneer in the microbiome field, Finch has established a diverse portfolio of microbiome assets with potential applications across various therapeutic areas. The company's mission is to harness the therapeutic potential of the microbiome to improve patient outcomes globally.
Finch Therapeutics has attracted notable investors and industry experts who support its groundbreaking work in microbial therapies. Among its key achievements, Finch has developed CP101, a therapeutic candidate for recurrent C. difficile infection, although it recently decided to discontinue its Phase trial to focus on maximizing the value of its intellectual property and other assets. The company's innovative approach and commitment to advancing microbiome science have positioned it as a significant player in the biopharmaceutical industry, impacting patient care worldwide.
